Affymetrix, Inc. (AFFX)

Affymetrix, Inc. (AFFX) - Tycho Peterson at JP Morgan

In midday trading, the stock advanced $170, or 30 percent, to $737 Based on the results, JPMorgan analyst Tycho Peterson upgraded Affymetrix shares to "Neutral" from "Underweight" He said the stock presents little risk right now because of solid demand for its new products "Following a challenging 2009, AffyMetrix reported better than expected fourth quarter results as early demand for GeneTitan and Axiom began to take hold and strong instrument placements more than offset headwinds from pharma consolidation," he said He added that Affymetrix should be profitable on an operating basis in 2010, and will get a boost from stimulus funds later in the year 

Affymetrix, Inc. (AFFX) - Matthew Scalo at Canaccord Adams

"It will probably take another five years before we see the $1,000 price range (per genome)," S&P Equity Research analyst Jeffery Loo said Illumina, which also has an array business, competes with the likes of Life Technologies Corp, Affymetrix Inc, Roche, Agilent Technologies Inc and Helicos BioSciences Corp EVOLVE OR PERISH But as technology changes the way genetic analysis is conducted, companies are increasingly seeing the need to jump on the gene sequencing bandwagon sooner rather than later Affymetrix, a pure play array maker, has seen its shares fall about 20 percent and its investment rating downgraded by at least two brokerages, since the launch of the HiSeq 2000 Rival array makers have not taken as much of a hit, as they have alternative revenue streams or are already pursuing a gene sequencing business "There will always be room for arrays but Affymetrix is in need of new technologies out there that address growing markets," Canaccord Adams analyst Matthew Scalo said 

Affymetrix, Inc. (AFFX) - Jeffrey Loo at Standard & Poor''s Equity Group

"It will probably take another five years before we see the $1,000 price range (per genome)," S&P Equity Research analyst Jeffery Loo said Illumina, which also has an array business, competes with the likes of Life Technologies Corp, Affymetrix Inc, Roche, Agilent Technologies Inc and Helicos BioSciences Corp EVOLVE OR PERISH But as technology changes the way genetic analysis is conducted, companies are increasingly seeing the need to jump on the gene sequencing bandwagon sooner rather than later Affymetrix, a pure play array maker, has seen its shares fall about 20 percent and its investment rating downgraded by at least two brokerages, since the launch of the HiSeq 2000 Rival array makers have not taken as much of a hit, as they have alternative revenue streams or are already pursuing a gene sequencing business "There will always be room for arrays but Affymetrix is in need of new technologies out there that address growing markets," Canaccord Adams analyst Matthew Scalo said 

Affymetrix, Inc. (AFFX) - Anthony Butler at Barclays Capital

Rival array makers have not taken as much of a hit, as they have alternative revenue streams or are already pursuing a gene sequencing business "There will always be room for arrays but Affymetrix is in need of new technologies out there that address growing markets," Canaccord Adams analyst Matthew Scalo said Analysts like Barclays Capital's Tony Butler question the company's ability to be profitable in the future, especially given its heavy dependence on the mature gene expression market Gene expression is a type of genetic analysis done on arrays that looks at which genes are being expressed, and can be used, for example, to determine an individual's susceptibility to cancer or the ability to respond to treatment 

Affymetrix, Inc. (AFFX) - Anthony Butler at Barclays Capital

Yet, the exponential jump in advancements could make some companies genetic waste California based Affymetrix ( AFFX ) might be riding the double helix to extinction The company, which has traded in a range of $178 to $1006 over the last 52 weeks, manufactures genetic analysis testing that uses micro array technology The technology that Affymetrix develops is quickly becoming obsolete, or so analysts believe Barclays Capital analyst C Anthony Butler downgraded the company on Wednesday morning to Underweight from Equalweight, as well as lowering his price target to $3 from $6 

Affymetrix, Inc. (AFFX) - Minyanville

Evolution of Technology Leaves Affymetrix Behind . By Lisa LaMotta The genetics company is riding the double helix to extinction 

Affymetrix, Inc. (AFFX) - Anthony Butler at Barclays Capital

NEW YORK , Shares of genetic analysis technology company Affymetrix Inc dropped Wednesday after an analyst said rival devices are making Affymetrix products "obsolete." Barclays analyst Charles Anthony Butler downgraded Affymetrix shares to "Underweight" from "Equal Weight," and cut his price target in half, to $3 per share Shares of the Santa Clara, Calif, company sank 69 cents, or 11 percent, to $575 in afternoon trading Butler said the thinks "new technologies are rapidly rendering the company's products obsolete" 

Affymetrix, Inc. (AFFX) - Deutsche Bank

, Analysts at Deutsche Bank Securities upgrade Affymetrix (AFFX) from "sell" to "hold."  

Affymetrix, Inc. (AFFX) - Ross Muken at Deutsche Bank

Affymetrix said it expects to sell more of its Axiom Genotyping system this quarter, but sales of consumable products that are used with Axiom will be slow as customers start using them. On Oct. 14, Affymetrix said Kaiser Permanente and the University of California at San Francisco will buy some Axiom systems to conduct a genetic analysis project. Axiom is designed to help researchers find genetic variations linked with complex diseases. In a note to clients, analyst Ross Muken of Deutsche Bank said genotyping revenue was weak in the third quarter due to a slowdown in research, and Affymetrix's costs increased. Muken predicted larger losses in 2009 and 2010 for Affymetrix, and kept a "sell" rating on the stock 

Affymetrix, Inc. (AFFX) - The Street.com

NEW YORK (AP) — Shares of Affymetrix Inc dropped sharply Thursday after the genetic analysis technology company posted disappointing third quarter results and offered a soft revenue forecast for the fourth quarter. Shares of the Santa Clara, Calif., company tumbled $1.66, or 18.7 percent, to $7.20 in afternoon trading. On Wednesday, Affymetrix reported a larger loss and less revenue than Wall Street expected, and it said it expects $82 million to $85 million in revenue in the current quarter. 

Affymetrix, Inc. (AFFX) - Ross Muken at Deutsche Bank

Deutsche Bank analyst Ross Muken said in a note to clients the company expects some stimulus benefit in the quarter but does not expect meaningful benefits until the first half of 2010. Companies such as Affymetrix, Life Technologies Corp ( LIFE.O ) and Illumina Inc ( ILMN.O ). which provide technology for genetic analysis. stand to benefit from President Barack Obama's $787 billion stimulus measure that includes $10 billion for the NIH. "You had a stock that had high expectations going in to the quarter, you have a quarter that came out to be a miss, with fairly conservative expectations on the fourth quarter, and so the stock is giving up a lot of the run up it had after the last quarter," Robert W Baird analyst Quintin Lai said. 

Affymetrix, Inc. (AFFX) - Quintin Lai at Robert W. Baird & Company

Deutsche Bank analyst Ross Muken said in a note to clients the company expects some stimulus benefit in the quarter but does not expect meaningful benefits until the first half of 2010. Companies such as Affymetrix, Life Technologies Corp ( LIFE.O ) and Illumina Inc ( ILMN.O ). which provide technology for genetic analysis. stand to benefit from President Barack Obama's $787 billion stimulus measure that includes $10 billion for the NIH. "You had a stock that had high expectations going in to the quarter, you have a quarter that came out to be a miss, with fairly conservative expectations on the fourth quarter, and so the stock is giving up a lot of the run up it had after the last quarter," Robert W Baird analyst Quintin Lai said.